Abstract: Methamphetamine (MA) dependence is a significant health problem in South Africa and the U.S. In South Africa, a shift in policy focus is required away from allocating health resources primarily to HIV/AIDS and TB and toward the financial, social and personal consequences of untreated stimulant addiction. In response to PAR 14-331, this application proposes to build capacity for a new linkage of productive teams of clinical researchers at UCLA and the University of Cape Town to conduct studies on the neurobiological foundation of treatment for stimulant dependence. The research direction is innovative in linking findings from neuroscience with clinical outcomes using contingency management (CM) to identify changes in brain structure and function that emerge during purely behavioral therapy. The knowledge gained may guide development of optimally effective behavioral and/or medication therapies. The application design will correlate MA-abstinence outcomes from an 8-week program of voucher-based incentives using an escalating schedule for 30 treatment-seeking, MA-dependent individuals with scores on tasks of working memory and assessments of neuropsychological and demographic status. At the beginning and end of the CM program, participants will participate in MRI scans while performing a working memory task, and will complete a battery of select neurocognitive and psychological assays to address two specific aims: (1) to determine whether changes in neural function within front striatal circuitry from baseline to end of the 8- week CM program are associated with parallel changes in measures of cognitive control and impulsivity and with MA abstinence outcomes; (2) to determine whether structural changes in front striatal circuitry over the 8-week CM intervention correspond with neurocognitive, psychological and MA abstinence measures. Findings from this study will describe associations between: (1) functional and structural indices of brain areas that support working memory, cognitive control/inhibition; (2) performance on select neurocognitive and psychological assessments; and (3) associations between these with MA abstinence outcomes. Study activities and the neuroscience data generated will provide preliminary data for a larger, adequately powered study that will test ways to optimize behavioral therapies for treating stimulant use disorder.
Project Number: 3R21DA040492-02S1 (2017); 5R21DA040492-02 (2016)
https://reporter.nih.gov/search/WrJtBSqGgUKo9EPZYXxZsA/project-details/9480137
Contact PI/ Project Leader
SHOPTAW, STEVEN J, PROFESSOR (SSHOPTAW@MEDNET.UCLA.EDU)
Organization
UNIVERSITY OF CALIFORNIA LOS ANGELES
PUBLIC HEALTH RELEVANCE: Statement Methamphetamine addiction (MA) is a global health problem with high prevalence and great social and health costs in the United States and in the Republic of South Africa and there is a strong need for development and implementation of effective MA treatment approaches. This project will correlate outcomes from an 8-week program of contingency management with findings from pre- and post- treatment neuroimaging and neurocognitive assessments to identify structures and/or processes that may represent targets for development of novel behavioral and/or medication therapies. The public health relevance of this application is enhanced by its effort to develop capacity for a productive and impactful neuroscience research agenda between groups of strong clinical scientists in the U.S. and in the Republic of South Africa.
FOA: PAR-14-331/ Study Section: Special Emphasis Panel[ZRG1-BDCN-N(55)R]
Project Start Date: 01-September-2015
Project End Date: 31-August-2018
Budget Start Date: 01-September-2016
Budget End Date: 31-August-2018
NIH Categorical Spending
Funding IC: NATIONAL INSTITUTE ON DRUG ABUSE / FY Total Cost by IC: $9,353